Posts by Mike Mooney
Guest Feature: Capturing Voices – Considerations When Writing YOUR Book
The grief caused by FTD is persistent, lasting well beyond the end of the FTD journey for family and friends. However, as author and support group volunteer Scott Rose shares in the…
Read MoreResearcher Discusses Integrating Genetic Testing Into Routine FTD/ALS Care in Podcast Interview
Offering genetic testing to persons diagnosed with FTD/ALS disorders should be a routine part of clinical care, Laynie Dratch, ScM, CGC, of Penn Medicine, said in a December 2023 interview…
Read MoreNews Report on Tallahassee Couple’s FTD Journey Highlights Challenges of Misdiagnosis
A report aired by Tallahassee news station WTXL27 shares how FTD has affected the lives of a local couple. Larry Davis told reporter Maya Sargent that his FTD diagnosis and…
Read MoreVolunteer Update: AFTD Ambassadors Welcome New Cohort
The AFTD Ambassador program was launched in 2019 as a new opportunity for AFTD’s volunteer leadership. Since then, the initial cohort of Ambassadors has grown into an enthusiastic, highly motivated…
Read MorePublic Benefits When Notable Names Share Neurological Challenges, UCLA Professor Writes
In an opinion piece published last month in the Los Angeles Times, Keith Vossel, MD, of the University of California, Los Angeles, writes that celebrities and politicians who share their…
Read MoreAdvancing Hope: AFTD Holds 2023 Holloway Summit Meeting on Biomarkers for FTD
The second annual AFTD Holloway Summit, focused on biomarkers for FTD, was held from November 30 to December 1 in Miami Beach, FL. More than 50 attendees from academia, industry,…
Read MoreDear HelpLine: Dealing With Genetic Uncertainty
Dear HelpLine, Each time I visit home for the holidays and see firsthand how FTD has affected my parent, my anxiety increases. Is it normal to worry that other family…
Read MoreAFTD and ADDF Extend Treat FTD Fund Program Through 2035
AFTD and the Alzheimer’s Drug Discovery Foundation (ADDF) have committed to extending the Treat FTD Fund program through 2035, providing an additional ten years of support to accelerate treatment development…
Read MoreThe Lived Experience of FTD: Grief on the FTD Journey
The following article was written by members of AFTD’s Persons with FTD Advisory Council, who work to ensure that the insights and voices of people living with FTD help guide…
Read MorePassage Bio Announces Hopeful Initial Data from Phase 1/2 Clinical Trial
Passage Bio released promising preliminary results from its phase 1/2 clinical trial evaluating an experimental treatment for FTD cases caused by a GRN genetic mutation (FTD-GRN). The “upliFT-D” trial is…
Read More